276 related articles for article (PubMed ID: 26597325)
1. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study.
Jack CR; Therneau TM; Wiste HJ; Weigand SD; Knopman DS; Lowe VJ; Mielke MM; Vemuri P; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2016 Jan; 15(1):56-64. PubMed ID: 26597325
[TBL] [Abstract][Full Text] [Related]
2. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
3. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Rocca WA; Knopman DS; Mielke MM; Lowe VJ; Senjem ML; Gunter JL; Preboske GM; Pankratz VS; Vemuri P; Petersen RC
Lancet Neurol; 2014 Oct; 13(10):997-1005. PubMed ID: 25201514
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
[TBL] [Abstract][Full Text] [Related]
5. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
[TBL] [Abstract][Full Text] [Related]
6. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
[TBL] [Abstract][Full Text] [Related]
7. Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study.
Vemuri P; Lesnick TG; Przybelski SA; Knopman DS; Machulda M; Lowe VJ; Mielke MM; Roberts RO; Gunter JL; Senjem ML; Geda YE; Rocca WA; Petersen RC; Jack CR
Neurology; 2016 Mar; 86(12):1128-35. PubMed ID: 26911640
[TBL] [Abstract][Full Text] [Related]
8. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease biomarker states.
Vos SJ; Fagan AM
Lancet Neurol; 2016 Jan; 15(1):25-6. PubMed ID: 26597326
[No Abstract] [Full Text] [Related]
10. Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study.
Mielke MM; Savica R; Wiste HJ; Weigand SD; Vemuri P; Knopman DS; Lowe VJ; Roberts RO; Machulda MM; Geda YE; Petersen RC; Jack CR
Neurology; 2014 Jan; 82(1):70-6. PubMed ID: 24371306
[TBL] [Abstract][Full Text] [Related]
11. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings.
Jack CR; Wiste HJ; Weigand SD; Knopman DS; Mielke MM; Vemuri P; Lowe V; Senjem ML; Gunter JL; Reyes D; Machulda MM; Roberts R; Petersen RC
Brain; 2015 Dec; 138(Pt 12):3747-59. PubMed ID: 26428666
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.
Roberts RO; Aakre JA; Kremers WK; Vassilaki M; Knopman DS; Mielke MM; Alhurani R; Geda YE; Machulda MM; Coloma P; Schauble B; Lowe VJ; Jack CR; Petersen RC
JAMA Neurol; 2018 Aug; 75(8):970-979. PubMed ID: 29710225
[TBL] [Abstract][Full Text] [Related]
13. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
[TBL] [Abstract][Full Text] [Related]
14. White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration.
Kantarci K; Schwarz CG; Reid RI; Przybelski SA; Lesnick TG; Zuk SM; Senjem ML; Gunter JL; Lowe V; Machulda MM; Knopman DS; Petersen RC; Jack CR
JAMA Neurol; 2014 Dec; 71(12):1547-54. PubMed ID: 25347157
[TBL] [Abstract][Full Text] [Related]
15. Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia.
Vassilaki M; Aakre JA; Kremers WK; Mielke MM; Geda YE; Machulda MM; Knopman DS; Coloma PM; Schauble B; Vemuri P; Lowe VJ; Jack CR; Petersen RC; Roberts RO
J Am Geriatr Soc; 2018 Dec; 66(12):2274-2281. PubMed ID: 30462843
[TBL] [Abstract][Full Text] [Related]
16. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions.
Ossenkoppele R; van der Flier WM; Verfaillie SC; Vrenken H; Versteeg A; van Schijndel RA; Sikkes SA; Twisk J; Adriaanse SM; Zwan MD; Boellaard R; Windhorst AD; Barkhof F; Scheltens P; Lammertsma AA; van Berckel BN
Neurology; 2014 May; 82(20):1768-75. PubMed ID: 24748672
[TBL] [Abstract][Full Text] [Related]
18. Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment.
Knopman DS; Jack CR; Lundt ES; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Machulda MM; Roberts RO; Boeve BF; Jones DT; Petersen RC
JAMA Neurol; 2015 Dec; 72(12):1475-83. PubMed ID: 26437123
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework.
Jack CR; Therneau TM; Weigand SD; Wiste HJ; Knopman DS; Vemuri P; Lowe VJ; Mielke MM; Roberts RO; Machulda MM; Graff-Radford J; Jones DT; Schwarz CG; Gunter JL; Senjem ML; Rocca WA; Petersen RC
JAMA Neurol; 2019 Oct; 76(10):1174-1183. PubMed ID: 31305929
[TBL] [Abstract][Full Text] [Related]
20. Validation of prognostic biomarker scores for predicting progression of dementia in patients with amnestic mild cognitive impairment.
Moreland J; Urhemaa T; van Gils M; Lötjönen J; Wolber J; Buckley CJ
Nucl Med Commun; 2018 Apr; 39(4):297-303. PubMed ID: 29419659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
